The neuroprotective effect of BSA-based nanocurcumin against 6-OHDA-induced cell death in SH-SY5Y cells

Document Type : Short communication


1 Students Research Committee, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran

2 Department of Pathology, Transplant Research Center, Shiraz University of Medical Sciences, Shiraz, Iran

3 Nanobiology and Nanomedicine Research Centre, Shiraz University of Medical sciences, Shiraz, Iran

4 Shiraz Neuroscience Research Centre, Shiraz University of Medical sciences, Shiraz, Iran


Objective: Parkinson’s disease (PD) is regarded as the second most common neurodegenerative disease affecting elderly population. There is a tendency toward finding natural cures to suppress the initiation and progression of this disease. Some epidemiological studies indicated lower incidence of PD in populations that consume curry. Curcumin, as the main ingredient of turmeric, has been supposed to have a protective role against PD progression. However, low bioavailability of curcumin is still a challenge in evaluation of the therapeutic potential of this substance. In this study, we aimed to produce a BSA-based nanocurcumin to assess its effect on 6-hydroxydopamine (6-OHDA)-induced death and Akt signaling disruption in SH-SY5Y cells.
Materials and Methods: BSA-based nanocurcumin was produced using desolvation method. Human neuroblastoma cells were treated with OHDA with/without different doses of nanocurcumin and MTT test was used to assess their viability besides observing cells morphological changes. The protective doses of nanocurcumine were chosen according to MTT results and western blot studies were done to assess p-Akt/t-Akt ratio.
Results: 6-OHDA exposure led to decreased cell viability, while nanocurcumin at doses of 400 and 500 nM prevented cell death. Moreover, this nanoformulation of curcumin restored p-Akt/t-Akt decrement induced by 6-OHDA. The protective effect of BSA-based nanocurcumin was estimated to be at least 4 time higher than that of natural curcumin according to the MTT results.
Conclusion: It seems that BSA-based nanocurcumin can be regarded as a potent substitute for natural curcumin in protecting SH-SY5Y cell as a cellular model of PD.


Main Subjects

Amiri E, Ghasemi R, Moosavi M. 2016. Agmatine Protects Against 6-OHDA-Induced Apoptosis, and ERK and Akt/GSK Disruption in SH-SY5Y Cells. Cell Mol Neurobiol, 36:829-838.
Aniesrani Delfiya DS, Thangavel K, Amirtham D. 2016. Preparation of Curcumin Loaded Egg Albumin Nanoparticles Using Acetone and Optimization of Desolvation Process. Protein J, 35:124-135.
Blesa J, Przedborski S. 2014. Parkinson's disease: animal models and dopaminergic cell vulnerability. Front Neuroanat, 8:155.
Blum D, Torch S, Nissou MF, Benabid AL, Verna JM. 2000. Extracellular toxicity of 6-hydroxydopamine on PC12 cells. Neurosci Lett, 283:193-196.
Bove J, Prou D, Perier C, Przedborski S. 2005. Toxin-induced models of Parkinson's disease. NeuroRx, 2:484-494.
Cai Z, Zeng W, Tao K, Lu F, Gao G, Yang Q.  2015. Myricitrin alleviates MPP(+)-induced mitochondrial dysfunction in a DJ-1-dependent manner in SN4741 cells. Biochem Biophys Res Commun, 458:227-233.
Chen G, Bower KA, Ma C, Fang S, Thiele CJ, Luo J. 2004. Glycogen synthase kinase 3beta (GSK3beta) mediates 6-hydroxydopamine-induced neuronal death. FASEB J, 18:1162-1164.
Cheng KK, Yeung CF, Ho SW, Chow SF, Chow AH, Baum L. 2013. Highly stabilized curcumin nanoparticles tested in an in vitro blood-brain barrier model and in Alzheimer's disease Tg2576 mice. Aaps J, 15:324-336.
Cheung YT, Lau WK, Yu MS, Lai CS, Yeung SC, So KF, Chang RC. 2009. Effects of all-trans-retinoic acid on human SH-SY5Y neuroblastoma as in vitro model in neurotoxicity research. Neurotoxicology, 30:127-135.
Datta SR, Brunet A, Greenberg ME. 1999. Cellular survival: a play in three Akts. Genes Dev, 13:2905-2927.
Driver JA, Logroscino G, Gaziano JM, Kurth T. 2009. Incidence and remaining lifetime risk of Parkinson disease in advanced age. Neurology, 72:432-438.
Franke TF, Cantley LC. 1997. Apoptosis. A Bad kinase makes good. Nature, 390:116-117.
Ghasemi R, Moosavi M, Zarifkar A, Rastegar K, Maghsoudi N. 2015. The Interplay of Akt and ERK in Abeta Toxicity and Insulin-Mediated Protection in Primary Hippocampal Cell Culture. J Mol Neurosci, 57:325-334.
Greene LA, Levy O, Malagelada C. 2011. Akt as a victim, villain and potential hero in Parkinson's disease pathophysiology and treatment. Cell Mol Neurobiol, 31:969-978.
Gu M, Cooper JM, Taanman JW, Schapira AH. 1998. Mitochondrial DNA transmission of the mitochondrial defect in Parkinson's disease. Ann Neurol, 44:177-186
Hwang O. 2013. Role of oxidative stress in Parkinson's disease. Exp Neurobiol, 22:11-17.
Jaroonwitchawan T, Chaicharoenaudomrung N, Namkaew J, Noisa P. 2017. Curcumin attenuates paraquat-induced cell death in human neuroblastoma cells through modulating oxidative stress and autophagy. Neurosci Lett, 636:40-47.
Jithan AV, Madhavi K, Madhavi M, Prabhakar K. 2011. Preparation and characterization of albumin nanoparticles encapsulating curcumin intended for the treatment of breast cancer. International Journal of Pharmaceutical Investigation, 1:119-125.
Khopde SM, Priyadarsini KI, Guha SN, Satav JG, Venkatesan P, Rao MN. 2000. Inhibition of radiation-induced lipid peroxidation by tetrahydrocurcumin: possible mechanisms by pulse radiolysis. Biosci Biotechnol Biochem, 64:503-509
Li L, Braiteh FS, Kurzrock R. 2005. Liposome-encapsulated curcumin: in vitro and in vivo effects on proliferation, apoptosis, signaling, and angiogenesis. Cancer, 104:1322-1331.
Ljungdahl A, Hokfelt T, Jonsson G, Sachs C. 1971. Autoradiographic demonstration of uptake and accumulation of 3H-6-hydroxydopamine in adrenergic nerves. Experientia, 27:297-299.
Mourtas S, Lazar AN, Markoutsa E, Duyckaerts C, Antimisiaris SG. 2014. Multifunctional nanoliposomes with curcumin-lipid derivative and brain targeting functionality with potential applications for Alzheimer disease. Eur J Med Chem, 80:175-183.
Nair P, Malhotra A, Dhawan DK. 2015. Curcumin and quercetin trigger apoptosis during benzo(a)pyrene-induced lung carcinogenesis. Mol Cell Biochem, 400:51-56.
Nazari QA, Takada-Takatori Y, Hashimoto T, Imaizumi A, Izumi Y, Akaike A, Kume T. 2014. Potential protective effect of highly bioavailable curcumin on an oxidative stress model induced by microinjection of sodium nitroprusside in mice brain. Food Funct, 5:984-989.
Nogueira V, Park Y, Chen CC, Xu PZ, Chen ML, Tonic I, Unterman T, Hay N. 2008. Akt determines replicative senescence and oxidative or oncogenic premature senescence and sensitizes cells to oxidative apoptosis. Cancer cell, 14:458-470.
Pan MH, Huang TM, Lin JK. 1999. Biotransformation of curcumin through reduction and glucuronidation in mice. Drug Metab Dispos, 27:486-494.
Prasad S, Gupta SC, Tyagi AK, Aggarwal BB. 2014. Curcumin, a component of golden spice: from bedside to bench and back. Biotechnol Adv, 32:1053-1064.
Rein MJ, Renouf M, Cruz-Hernandez C, Actis-Goretta L, Thakkar SK, da Silva Pinto M. 2013. Bioavailability of bioactive food compounds: a challenging journey to bioefficacy. Br J Clin Pharmacol, 75:588-602.
Scheepens A, Tan K, Paxton JW. 2010. Improving the oral bioavailability of beneficial polyphenols through designed synergies. Genes Nutr, 5:75-87.
Schule B, Pera RA, Langston JW. 2009. Can cellular models revolutionize drug discovery in Parkinson's disease? Biochim Biophys Acta, 1792:1043-1051.
Shin KS, Choi HS, Zhao TT, Suh KH, Kwon IH, Choi SO, Lee MK. 2013. Neurotoxic effects of berberine on long-term L-DOPA administration in 6-hydroxydopamine-lesioned rat model of Parkinson's disease. Arch Pharm Res, 36:759-767.
Siddique YH, Naz F, Jyoti S. 2014. Effect of curcumin on lifespan, activity pattern, oxidative stress, and apoptosis in the brains of transgenic Drosophila model of Parkinson's disease. Biomed Res Int, 2014:606928.
Song JX, Shaw PC, Wong NS, Sze CW, Yao XS, Tang CW, Tong Y, Zhang YB. 2012. Chrysotoxine, a novel bibenzyl compound selectively antagonizes MPP(+), but not rotenone, neurotoxicity in dopaminergic SH-SY5Y cells. Neurosci Lett, 521:76-81.
Takahashi M, Uechi S, Takara K, Asikin Y, Wada K. 2009. Evaluation of an oral carrier system in rats: bioavailability and antioxidant properties of liposome-encapsulated curcumin. J Agric Food Chem, 57:9141-9146.
Tsai YM, Chien CF, Lin LC, Tsai TH. 2011a. Curcumin and its nano-formulation: the kinetics of tissue distribution and blood-brain barrier penetration. Int J Pharm, 416:331-338.
Tsai YM, Jan WC, Chien CF, Lee WC, Lin LC, Tsai TH. 2011b. Optimised nano-formulation on the bioavailability of hydrophobic polyphenol, curcumin, in freely-moving rats. Food Chem, 127:918-925.
Vandita K, Shashi B, Santosh KG, Pal KI. 2012. Enhanced apoptotic effect of curcumin loaded solid lipid nanoparticles. Mol Pharm, 9:3411-3421.
Young NA, Bruss MS, Gardner M, Willis WL, Mo X, Valiente GR, Cao Y, Liu Z, Jarjour WN, Wu LC. 2014. Oral administration of nano-emulsion curcumin in mice suppresses inflammatory-induced NFkappaB signaling and macrophage migration. PloS one, 9:e111559.